Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
4.110
+0.140 (3.53%)
May 2, 2025, 4:00 PM EDT - Market closed
Contineum Therapeutics Stock Forecast
CTNM's stock price has decreased by -73.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Contineum Therapeutics stock have an average target of 24.8, with a low estimate of 16 and a high estimate of 31. The average target predicts an increase of 503.41% from the current stock price of 4.11.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +459.61% | Mar 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $25 | Buy | Initiates | $25 | +508.27% | Mar 7, 2025 |
| Baird | Baird | Buy Maintains $32 → $16 | Buy | Maintains | $32 → $16 | +289.29% | Mar 7, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +654.26% | Jan 9, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $32 → $31 | Buy | Maintains | $32 → $31 | +654.26% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
5.10M
Revenue Next Year
n/a
from 5.10M
EPS This Year
-2.30
from -2.18
EPS Next Year
-2.97
from -2.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 31.5M | n/a | n/a |
| Avg | 5.1M | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.34 | -2.57 | -2.79 |
| Avg | -2.30 | -2.97 | -2.91 |
| Low | -2.69 | -3.87 | -3.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.